UPDATE: Stifel Reiterates on Conatus Pharmaceuticals on HCV-POLT Strategy Shift

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT ), but lowered the price target from $16.00 to $13.00. In the report, Stifel noted, “GAAP net loss of $3.3M was roughly in-line with our $2.5M estimate – with slightly-higher-than-expected R&D spend